Inflammatory breast cancer (IBC) is a rare and very aggressive disease in which cancer cells block lymph vessels in the skin of the breast. This type of breast cancer is called “inflammatory” because the breast often looks swollen and red, or “inflamed.”
Inflammatory breast cancer accounts for 1 to 5 percent of all breast cancers diagnosed in the United States.
Most inflammatory breast cancers are invasive ductal carcinomas, which means they developed from cells that line the milk ducts of the breast and then spread beyond the ducts.
Inflammatory breast cancer progresses rapidly, often in a matter of weeks or months. Inflammatory breast cancer is either stage III or IV at diagnosis, depending on whether cancer cells have spread only to nearby lymph nodes or to other tissues as well.
Additional features of inflammatory breast cancer include the following:
- Compared with other types of breast cancer, inflammatory breast cancer tends to be diagnosed at younger ages (median age of 57 years, compared with a median age of 62 years for other types of breast cancer).
- It is more common and diagnosed at younger ages in African American women than in white women. The median age at diagnosis in African American women is 54 years, compared with a median age of 58 years in white women.
- Inflammatory breast tumors are frequently hormone receptor negative, which means that hormone therapies, such as tamoxifen, that interfere with the growth of cancer cells fueled by estrogen may not be effective against these tumors.
- Inflammatory breast cancer is more common in obese women than in women of normal weight.
Like other types of breast cancer, inflammatory breast cancer can occur in men, but usually at an older age (median age at diagnosis of 66.5 years) than in women.
What are the symptoms of inflammatory breast cancer?
Symptoms of inflammatory breast cancer include swelling (edema) and redness (erythema) that affect a third or more of the breast.
The skin of the breast may also appear pink, reddish purple, or bruised. In addition, the skin may have ridges or appear pitted, like the skin of an orange (called peau d’orange).
These symptoms are caused by the buildup of fluid (lymph) in the skin of the breast. This fluid buildup occurs because cancer cells have blocked lymph vessels in the skin, preventing the normal flow of lymph through the tissue.
Sometimes, the breast may contain a solid tumor that can be felt during a physical exam, but, more often, a tumor cannot be felt.
Other symptoms of inflammatory breast cancer include a rapid increase in breast size; sensations of heaviness, burning, or tenderness in the breast; or a nipple that is inverted (facing inward).
Swollen lymph nodes may also be present under the arm, near the collarbone, or in both places.
It is important to note that these symptoms may also be signs of other diseases or conditions, such as an infection, injury, or another type of breast cancer that is locally advanced.
For this reason, women with inflammatory breast cancer often have a delayed diagnosis of their disease.
How is inflammatory breast cancer different from the more common types of breast cancer?
Inflammatory breast cancer causes symptoms that are often different from those of more common breast cancers. It often does not cause a breast lump, and it might not show up on a mammogram.
Because it doesn’t look like a typical breast cancer, it can be harder to diagnose.
IBC tends to develop at a younger age than the more common form of breast cancer (at an average age 52 versus 57 for non-inflammatory breast cancer).
Also, African-American women appear to be at higher risk of IBC than white women. It also is more common among women who are overweight or obese.
IBC also tends to be more aggressive—it grows and spreads much more quickly— than more common types of breast cancer.
Based on the way breast cancer is staged, it is never early stage breast cancer. It is always at least stage IIIB (locally advanced) when it is first diagnosed because the breast cancer cells have grown into the skin.
Often, though, it has already spread (metastasized) to distant parts of the body when it is diagnosed, making it stage IV.
The advanced stage of IBC, along with the tendency to grow and spread quickly, makes it harder to treat successfully than most other types of breast cancer.
Because of the way inflammatory breast cancer (IBC) grows and spreads, a distinct lump may not be noticeable during a clinical breast exam, breast self-exam, or even on a mammogram.
However, signs of IBC can be seen on the surface of the skin, and skin thickening often shows up on a mammogram and can be seen during a clinical breast exam or breast self-exam
Symptoms of IBC can develop very quickly, so women should pay attention to how the skin looks on their breasts and tell their doctors about any changes in skin texture or breast appearance.
In women who are pregnant or breastfeeding, breast redness and swelling is more often caused by an infection (mastitis) than by IBC, so doctors might try treatments like antibiotics for a short time first.
The possible diagnosis of IBC should be considered more strongly when a woman who is not pregnant or breastfeeding comes in with these symptoms.
Breast infection is less common in women who are not pregnant or breastfeeding, and even rarer in women after menopause. When infection occurs it is usually associated with fever or other signs of infection.
Following the American Cancer Society guidelines for early detection of breast cancer can improve a woman’s odds of finding most types of breast cancer early, when it can be treated most successfully.
Unfortunately, because IBC grows and spreads so fast, screening is not generally helpful for finding this disease early.
How is inflammatory breast cancer diagnosed?
Inflammatory breast cancer can be difficult to diagnose. Often, there is no lump that can be felt during a physical exam or seen in a screening mammogram.
In addition, most women diagnosed with inflammatory breast cancer have non-fatty (dense) breast tissue, which makes cancer detection in a screening mammogram more difficult.
Also, because inflammatory breast cancer is so aggressive, it can arise between scheduled screening mammograms and progress quickly.
The symptoms of inflammatory breast cancer may be mistaken for those of mastitis, which is an infection of the breast, or another form of locally advanced breast cancer.
To help prevent delays in diagnosis and in choosing the best course of treatment, an international panel of experts published guidelines on how doctors can diagnose and stage inflammatory breast cancer correctly.
Their recommendations are summarized below.
Minimum criteria for a diagnosis of inflammatory breast cancer include the following:
- A rapid onset of erythema (redness), edema (swelling), and a peau d’orange appearance and/or abnormal breast warmth, with or without a lump that can be felt.
- The above-mentioned symptoms have been present for less than 6 months.
- The erythema covers at least a third of the breast.
- Initial biopsy samples from the affected breast show invasive carcinoma.
Further examination of tissue from the affected breast should include testing to see if the cancer cells have hormone receptors (estrogen and progesterone receptors) or a mutation that causes them to make greater than normal amounts of the HER2 protein (HER2-positive breast cancer).
Imaging and staging tests should include the following:
- A diagnostic mammogram and an ultrasound of the breast and regional (nearby) lymph nodes.
- A PET scan or a CT scan and a bone scan to see if the cancer has spread to other parts of the body.
- Proper diagnosis and staging of cancer helps doctors develop the best treatment plan and estimate the likely outcome of the disease, including the chances for recurrence and survival.
How is inflammatory breast cancer treated?
Inflammatory breast cancer is treated first with systemic chemotherapy to help shrink the tumor, then with surgery to remove the tumor, followed by radiation therapy.
This approach to treatment is called a multimodal approach. Studies have found that women with inflammatory breast cancer who are treated with a multi-modal approach have better responses to therapy and longer survival.
Treatments used in a multimodal approach may include those described below.
Neoadjuvant chemotherapy: This type of chemotherapy is given before surgery and usually includes both anthracycline and taxane drugs.
At least six cycles of neoadjuvant chemotherapy given over the course of 4 to 6 months before attempting to remove the tumor has been recommended, unless the disease continues to progress during this time and doctors decide that surgery should not be delayed.
Targeted therapy: This type of treatment may be used if a woman’s biopsy samples show that her cancer cells have a tumor marker that can be targeted with specific drugs.
For example, inflammatory breast cancers often produce greater than normal amounts of the HER2 protein, which means they may respond positively to drugs, such as trastuzumab (Herceptin), that target this protein.
Anti-HER2 therapy can be given as part of neoadjuvant therapy and after surgery (adjuvant therapy). Studies have shown that women with inflammatory breast cancer who received trastuzumab in addition to chemotherapy have better responses to treatment and better survival.
Hormone therapy: If a woman’s biopsy samples show that her cancer cells contain hormone receptors, hormone therapy is another treatment option.
For example, breast cancer cells that have estrogen receptors depend on the female hormone estrogen to promote their growth.
Drugs such as tamoxifen, which prevent estrogen from binding to its receptor, and aromatase inhibitors such as letrozole, which block the body’s ability to make estrogen, can cause estrogen-dependent cancer cells to stop growing and die.
Surgery: The standard surgery for inflammatory breast cancer is a modified radical mastectomy. This surgery involves removal of the entire affected breast and most or all of the lymph nodes under the adjacent arm.
Often, the lining over the underlying chest muscles is also removed, but the chest muscles are preserved. Sometimes, however, the smaller chest muscle (pectoralis minor) may be removed, too.
Radiation therapy: Post-mastectomy radiation therapy to the chest wall under the breast that was removed is a standard part of multi-modal therapy for inflammatory breast cancer.
If a woman received trastuzumab before surgery, she may continue to receive it during postoperative radiation therapy. If breast reconstruction is planned, the sequencing of the radiation therapy and reconstructive surgery may be influenced by the method of breast reconstruction used.
If a breast implant is to be used, the preferred approach is to delay radiation therapy until after the reconstructive surgery.
If a woman’s own tissues are going to be used in breast reconstruction, it is preferable to delay reconstructive surgery until after the radiation therapy has been completed.
Adjuvant therapy: Adjuvant systemic therapy may be given after surgery to reduce the chance of cancer recurrence.
This therapy may include additional chemotherapy, antihormonal therapy, targeted therapy (such as trastuzumab), or some combination of these treatments.
Supportive/palliative care: The goal of supportive/palliative care is to improve the quality of life of patients who have a serious or life-threatening disease, such as cancer, and to provide support to their loved ones.